Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
2019 Investor Day presentation
ROVI updates its strategy in a meeting with shareholders, investors and analysts.
Mon, 25/11/2019 - 11:15
0 min
Español
0185.jpg
Download related document
Select rating
Give 2019 Investor Day presentation 1/5
Give 2019 Investor Day presentation 2/5
Give 2019 Investor Day presentation 3/5
Give 2019 Investor Day presentation 4/5
Give 2019 Investor Day presentation 5/5
No votes yet
Related
ROVI reports operating revenue growth of 26% and EBITDA growth of 106%
Operating revenue increased by 26% to 381.3 million euros in 2019, mainly driven by the strength of the specialty pharmaceutical...
6 min
26/02/2020
ROVI announces the commencement of the assessment process to obtain marketing...
ROVI filed its application for marketing authorisation for Doria® with the European health authorities, the European Medicines Agency (EMA...
2 min
31/01/2020
Financial Results Nine month period 2019 - Video
0 min
25/11/2019
See More
Email
Facebook
Twitter
LinkedIn
0185.jpg